Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.03B P/E - EPS this Y 5.70% Ern Qtrly Grth -
Income -194.94M Forward P/E -6.43 EPS next Y 21.30% 50D Avg Chg -6.00%
Sales 163.36M PEG -0.34 EPS past 5Y - 200D Avg Chg -15.00%
Dividend N/A Price/Book 2.34 EPS next 5Y 21.00% 52W High Chg -42.00%
Recommedations 1.90 Quick Ratio 3.37 Shares Outstanding 80.80M 52W Low Chg 3.00%
Insider Own 30.49% ROA -28.43% Shares Float 41.98M Beta 0.39
Inst Own 73.54% ROE -56.29% Shares Shorted/Prior 6.06M/5.51M Price 13.12
Gross Margin -45.61% Profit Margin -119.34% Avg. Volume 457,983 Target Price 24.20
Oper. Margin -106.10% Earnings Date May 1 Volume 349,404 Change -3.46%
About Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Deciphera Pharmaceuticals, Inc. News
04/09/24 Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
03/24/24 Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
03/14/24 Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?
03/07/24 Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report?
03/04/24 11 Best Small Cap Pharma Stocks to Invest In
02/28/24 Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 48.49%: Read This Before Placing a Bet
02/27/24 Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
02/12/24 Wall Street Analysts Believe Deciphera Pharmaceuticals, Inc. (DCPH) Could Rally 59.63%: Here's is How to Trade
02/08/24 Analysts Are Updating Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Estimates After Its Annual Results
02/07/24 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Q4 2023 Earnings Call Transcript
02/07/24 Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat
02/07/24 Q4 2023 Deciphera Pharmaceuticals Inc Earnings Call
02/06/24 Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
02/01/24 Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
02/01/24 Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
02/01/24 Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/30/24 Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Should You Buy?
01/29/24 Strong week for Deciphera Pharmaceuticals (NASDAQ:DCPH) shareholders doesn't alleviate pain of three-year loss
01/18/24 Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
01/08/24 Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
DCPH Chatroom

User Image Night_Owl_Biotech Posted - 4 days ago

The attachment notes the share price activity over the last 6 weeks of the 5 (relatively) recent commercial-stage oncology focused biopharmas with FDA approved cancer therapies anticipated to do at least $1B (or very close to $1B/year). All 5 are down 10-20% more or less consistent with the change in the XBI. It's our experience oncology focused biopharmas are more often acquired than non. Of course this does not mean it will be the case in the future. As always, our data could be wrong. This is not investment advice. $IMCR $SWTX $DAWN $DCPH $XBI

User Image Stu52 Posted - 1 week ago

$DCPH BFD …steve hoerter still ceo ( make believe ) ??? If so, a waste of time.

User Image Stock_Titan Posted - 1 week ago

$DCPH Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum https://www.stocktitan.net/news/DCPH/deciphera-pharmaceuticals-to-present-at-the-stifel-2024-virtual-bw7z1mo6rzy2.html

User Image Stu52 Posted - 1 week ago

$DCPH just a pos ! With the gang and Steve Hoerter

User Image Night_Owl_Biotech Posted - 03/27/24

The attachment lists all ind comm'l-stage bios with FDA approval since 1/1/17 (it may not reflect all 3/24 approvals). The left side notes oncology focused biopharmas. The right side = non-oncology. If we had to guess (that's all it'd be) which are candidates for near-term acquisition, it'd be $SWTX, $FENC, $DCPH, $ITCI & $RARE. SWTX is our pick for a near term buyout. SWTX's CEO is adamant Ogsiveo is a $1B+/year therapy just in the US (suggesting $2B globally) & B of A has ReNeu @ $1.5B in peak sales ($3B+ btwn the 2 products). SWTX may (again may) be worth more than IMGN because: 1. SWTX peak sales could be higher ($3B+ for SWTX per the experts v. $2.7B per IMGN) 2. Patents run 7 years longer (both SWTX products are patented thru 2043 where IMGN sales peak in 2036 per their 14A) 3. SWTX has 2 products to IMGN's 1 4. Both sell pills so gross margins should be the same Of course we could be wrong. We only suggest researching SWTX for yourself. Good luck.

User Image fda_tracker Posted - 1 month ago

$DCPH Phase 3 trial w/est Mar completion date NCT05059262: https://www.clinicaltrials.gov/study/NCT05059262 Trial Tracker: https://www.fdatracker.com/trial-tracker/

User Image Stu52 Posted - 1 month ago

$DCPH Leerink takes on all the losers ..$QURE $AGIO $NERV

User Image Hopenitsgood Posted - 1 month ago

$DCPH imagine if he DIDNT win virtually every state.......

User Image SorosSonosSatoshi Posted - 1 month ago

$DCPH eureka,. Code deciphered..13.666 flash crash level

User Image Stu512 Posted - 1 month ago

$DCPH 5 years and this pos stock and the narcissist senior execs, can NOT create value, Pfizer is eating their lunch, their market and laughing daily .

User Image Stock_Titan Posted - 02/27/24

$DCPH Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences https://www.stocktitan.net/news/DCPH/deciphera-pharmaceuticals-to-participate-in-upcoming-investor-bv6g3ilu3326.html

User Image Doozio Posted - 2 months ago

$DCPH wen 🧠⏰?

User Image Hopenitsgood Posted - 2 months ago

$DCPH oh man.....popcorn...I needs lots of popcorn....

User Image XavierLawlor1 Posted - 2 months ago

$LNZA $DCPH $BTBT Analyst price target for next week. https://profitable-trading-community.daytrading.network

User Image BraydenMagrath1 Posted - 2 months ago

$BTBT $DCPH $LNZA ACCOUNT CHALLENGE UPDATE Starting Balance: $3,700 Current Balance: $47,835 Goal: $100K by end of mar. Watch out for our next alert] https://profitable-trading-community.daytrading.network

User Image BondbutnotJames Posted - 2 months ago

$DCPH https://csimarket.com/stocks/news.php?code=DCPH&date=2024-02-07143416

User Image Stu512 Posted - 2 months ago

$DCPH POS..!!

User Image epsguid Posted - 2 months ago

$DCPH reported a loss of $0.54, consensus was ($0.58) via @eWhispers #epsbeat http://eps.sh/d/dcph

User Image Stock_Titan Posted - 2 months ago

$DCPH Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/DCPH/deciphera-pharmaceuticals-announces-fourth-quarter-and-full-year-fe8hsuorqur1.html

User Image BondbutnotJames Posted - 2 months ago

$DCPH https://finance.yahoo.com/news/deciphera-pharmaceuticals-present-guggenheim-healthcare-120000512.html

User Image BondbutnotJames Posted - 01/30/24

$DCPH State Street has increased their holdings to 2.470.813 shares.

User Image Stu52 Posted - 01/28/24

$DCPH Who Gives a F....they have to average DOWN from their BIG F'IN mistake , getting in bed with the narcissists that run the circus in Waltham, Ma

User Image Stu52 Posted - 01/28/24

$DCPH And so what

User Image BondbutnotJames Posted - 01/26/24

$DCPH Blackrock has increased its holdings in DCPH by more than half a million shares to 5.976 million shares.

User Image Stu52 Posted - 01/26/24

$SAVA ….hell even $SRPT is above its placement price of $80 done in 2022….$DCPH is even above its placement price of $10 done in 2022 !!!! You were saying RunwithbogusSAVA !!! “ where is SAVA today “ ..hahahaha …

User Image Stu52 Posted - 01/25/24

$DCPH

User Image Stu52 Posted - 01/25/24

$DCPH Pay attention L!!! The company is full of TRUMP TYPE NARCISSISTS. Piper says BUY awhile insiders are shoving shares out the door , you’re buying their “ given “ shares at a premium of $13 , lol…..knock yourselves out. The mgmt will sell again and again, they are all incompetent of creating value…you saw it in 2021 , November, the catastrophic SLIDE , their incompetence was unveiled

User Image Stu52 Posted - 01/25/24

$DCPH And Piper says BUY

User Image cctranscripts Posted - 01/23/24

Statement of acquisition of beneficial ownership by individuals https://www.conferencecalltranscripts.org/summary/?id=12886498 $DCPH

User Image STCKPRO Posted - 01/22/24

$DCPH NEW ARTICLE : Piper Sandler Remains a Buy on Deciphera Pharmaceuticals (DCPH) https://stck.pro/news/DCPH/73494314/

Analyst Ratings
JP Morgan Neutral Mar 20, 24
Stifel Buy Feb 7, 24
Stifel Buy Oct 31, 23
HC Wainwright & Co. Buy Oct 31, 23
JonesTrading Buy Oct 31, 23
Piper Sandler Overweight Oct 30, 23
HC Wainwright & Co. Buy Aug 10, 23
Stifel Buy Aug 10, 23
JMP Securities Market Outperform Jun 5, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Brightstar Associates LLC 10% Owner 10% Owner Jan 24 Buy 18.00 1,666,666 29,999,988 19,718,014 01/24/23
Flynn Daniel Lee Chief Scientific Off.. Chief Scientific Officer Jan 17 Sell 21.2413 2,403 51,043 43,695 01/19/23
Pitman Jama See Remarks See Remarks Jan 17 Sell 21.2413 1,603 34,050 35,058 01/19/23
Sherman Matthew L EVP & Chief Medical.. EVP & Chief Medical Officer Jan 17 Sell 21.2413 2,403 51,043 72,628 01/19/23
Martin Daniel C. Chief Commercial Off.. Chief Commercial Officer Jan 17 Sell 21.2413 1,603 34,050 48,389 01/19/23
Kelly Thomas Patrick Chief Financial Offi.. Chief Financial Officer Jan 17 Sell 21.2413 2,403 51,043 43,677 01/19/23
Brightstar Associates LLC 10% Owner 10% Owner Apr 29 Buy 10.00 1,478,978 14,789,780 18,051,348 04/29/22
Flynn Daniel Lee Chief Scientific Off.. Chief Scientific Officer Feb 16 Sell 9.05 1,366 12,362 47,866 02/18/22
Martin Daniel C. Chief Commercial Off.. Chief Commercial Officer Feb 16 Sell 9.05 1,146 10,371 48,668 02/18/22
Sherman Matthew L EVP & Chief Medical.. EVP & Chief Medical Officer Feb 16 Sell 9.05 984 8,905 76,790 02/18/22
Kelly Thomas Patrick Chief Financial Offi.. Chief Financial Officer Feb 16 Sell 9.05 1,368 12,380 47,848 02/18/22
Taylor Michael Douglas Director Director Apr 06 Option 1.89 8,000 15,120 8,000 04/06/21
Taylor Michael Douglas Director Director Apr 06 Sell 45.74 8,000 365,920 04/06/21
Kelly Thomas Patrick Chief Financial Offi.. Chief Financial Officer Sep 10 Option 1.89 9,000 17,010 10,040 09/10/20
Kelly Thomas Patrick Chief Financial Offi.. Chief Financial Officer Sep 10 Sell 46.05 9,000 414,450 7,040 09/10/20